Lymphokines
- Name
- Lymphokines
- Accession Number
- DBCAT002874
- Description
Soluble protein factors generated by activated lymphocytes that affect other cells, primarily those involved in cellular immunity.
- Drugs
Drug Drug Description Human interleukin-2 Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL). Teceleukin Teceleukin is under investigation in clinical trial NCT03610490 (Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Osteosarcoma, or Pancreatic Ductal Adenocarcinoma). Dialyzable leukocyte extract Transferon is comprised of several peptides mixed from human dialyzable leucocyte extracts and acts as an immunomodulator. It is thought to have widespread effects on the immune system, and effective... Denileukin diftitox A recombinant cytotoxic protein based on a combination of diphtheria toxin fragments and interleukin-2 used to treat cutaneous T-cell lymphoma by targeting the interleukin-2 receptor. Interferon gamma-1b A form of recombinant human interferon used to treat infections associated with chronic granulomatous disease and to slow the progression of severe malignant osteopetrosis. Aldesleukin A recombinant analog of interleukin-2 used to induce an adaptive immune response in the treatment of renal cell carcinoma. Bempegaldesleukin Bempegaldesleukin is under investigation in clinical trial NCT03729245 (A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib... ALT-801 ALT-801 is under investigation in clinical trial NCT01478074 (ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia). Tucotuzumab celmoleukin Tucotuzumab celmoleukin is under investigation in clinical trial NCT00016237 (Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous... Lorukafusp alfa Lorukafusp alfa is under investigation in clinical trial NCT01334515 (Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma). - Drugs & Drug Targets